Disc Medicine Inc (IRON)

NASD · Healthcare · Biotechnology · USA

Disc Medicine Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic diseases by targeting red blood cell formation and function. Its pipeline includes bitopertin for erythropoietic porphyrias, DISC-0974 for anemia in myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle cell disease.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Disc Medicine Inc stock.

Our verdict on IRON

Not valued: We cannot value this company yet.

ETFs with the most weight in IRON

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than IRON in Biotechnology

129 more in this industry show a wider margin of safety.

Is IRON undervalued or overvalued?

We do not publish a verdict on IRON yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of IRON?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.